NCT05991102

Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Combined chemotherapy and radiofrequency electromagnetic field treatment for patients with liver dominant refractory metastatic colorectal cancer

Detailed description

Charité Universitätsmedizin Berlin is currently the only German University Hospital with an available capacitive radiofrequency electromagnetic field treatment device. While there is only data available regarding the low toxicity profile of radiofrequency electromagnetic field treatment for various regions of the body including the abdomen there is no data available on the combined effect of TAS-102 and Bevacizumab and radiofrequency electromagnetic field treatment. The investigators aim to conduct a feasibility trial and plan to compare the results with data of a prospective trial with a comparable patient population.

Conditions

• Refractory Metastatic Colorectal Cancer

Interventions

Type	Name	Description
DEVICE	Radiofrequency electromagnetic field treatment	Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz

Timeline

• Start date: 2023-12-15
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2023-08-14
• Last updated: 2023-12-21

Locations

1 site across 1 country: Germany